[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100247241":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":11,"armGroups":22,"interventions":33,"overallOfficials":11,"centralContacts":42,"locations":11,"responsibleParty":48,"collaborators":11,"id":50,"slug":11,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":11},{"fullName":5,"class":6},"The First People's Hospital of Changzhou","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Overall survival",null,"5 years",[14],{"measure":15,"description":11,"timeFrame":16},"Adverse events","4 weeks",{"allocation":18,"interventionModel":19,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":11,"timePerspective":11,"maskingInfo":20},"NON_RANDOMIZED","PARALLEL",{"masking":21,"maskingDescription":11,"whoMasked":11},"NONE",[23,28],{"label":24,"type":6,"description":25,"interventionNames":26},"Temozolomide","Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg\u002Fm2\u002Fday for 5 consecutive days, repeated every 28 days",[27],"Drug: Temozolomide",{"label":29,"type":6,"description":30,"interventionNames":31},"Temozolomide+CIK","Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat",[32],"Biological: CIK",[34,37],{"type":35,"name":24,"description":25,"armGroupLabels":36,"otherNames":11},"DRUG",[24],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"BIOLOGICAL","CIK","The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat",[29],[43],{"name":44,"role":45,"phone":46,"phoneExt":11,"email":47},"Jingting Jiang, M.D","CONTACT","8651968870978","wcpjjt@163.com",{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100247241",false,"NCT02496988","Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas","A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas","Inclusion Criteria:\n\n* Subjects with documented histologically confirmed primary grade 4 advanced malignant glioma.\n* No more than 3 prior relapses or prior systemic treatments.\n* Recurrent disease documented by MRI after prior therapy.\n* Must have at least one site of bidimensionally measurable disease:\n\narchived tissue from the initial diagnosis of advanced malignant glioma or upon transformation to advanced malignant glioma are available for central review within approximately 4 weeks after enrollment.\n\n* Completed at least one full cycle of temozolomide of 200 mg\u002Fm2\u002Fday administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression.\n* Karnofsky performance status of 60 or more. Adequate organ and bone marrow function as defined by hematological and serum chemistry limits.\n* At least 18 years old.\n* Both men and women must practice adequate contraception.\n* Informed consent.\n\nExclusion Criteria:\n\n* Progressed while on temozolomide.\n* Evidence of acute intracranial or intratumoral hemorrhage \\> Grade 1.\n* Not recovered from the toxic effects of prior therapy.\n* Pregnant or breast feeding.\n* History of diabetes mellitus.\n* Uncontrolled intercurrent illness.\n* Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.\n* HIV positive.\n* Diagnosis of another malignancy may exclude subject from study.","ALL","18 Years","80 Years",{"count":60,"type":61},120,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.",[67,68],"Cytokine-Induced Killer Cells","Advanced Milignant Gliomas",[67,70,24],"Milignant Gliomas","NOT_YET_RECRUITING","2015-07-13",{"date":74,"type":61},"2015-07-14",{"date":76,"type":11},"2015-07",{"date":78,"type":61},"2030-07",{"name":5,"class":6}]